The insatiable appetite of companies for immuno-oncology assets is one of the main reasons that partnership and licensing deal flows remain on their torrid pace to eclipse the number and volume totals racked up last year.
After a slow start to the year, IPO activity for biotech companies picked up with 11 graduating to the public arena. However, the total amount raised was lower than the first quarter haul with most companies in the second quarter pricing their offerings within or below their ranges, and precious few transactions generated enough support to push above their original expectations reflecting the fact that the financial markets still remain volatile.
With the specter of antimicrobial resistance (AMR) posing a serious threat to global health systems, discovery of new antibiotics has become paramount in order to replenish the sparse medicine chest caused by a slowing of research and development in the field that began in the 1970s and persisted for almost 30 years.
With the specter of antimicrobial resistance (AMR) posing a serious threat to global health systems, discovery of new antibiotics has become paramount in order to replenish the sparse medicine chest caused by a slowing of research and development in the field that began in the 1970s and persisted for almost 30 years.
The American Society of Clinical Oncology (ASCO) annual meeting, which ran from June 3-7 in Chicago, is closely watched by analysts and investors alike, and favorable data presented at the event can advance a company's stock valuation significantly. Equally, candidate cancer therapies that do not live up to expectations will see their developers face the ire of investors.
SAN FRANCISCO – In sports, championship teams in one year invariably find it difficult to repeat their performances the following year. The biotech sector is experiencing a similar situation. While U.S. and European biotech companies established new financial performance records last year, the financial and business statistics six months into the current year indicate that the industry is on pace for a less than stellar 2016.
SAN FRANCISCO – Mitochondrial disease manifests itself when the mitochondria of the cell cannot produce the energy the body needs to support growth. Mitochondria and the diseases that result from the inappropriate functioning of those cells was the focus of several panel sessions at the BIO 2016 International Convention last week.
